Urology Times | News & Insights for Urologists & Health …
By Urology Times staff. October 10th 2024. "We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO. Phase 1/2 trial launches of Focal One robotic HIFU for BPH. By Hannah Clarke. October 9th 2024.
Prostate Cancer | Urology News & Expert Insights | Urology Times
4 天之前 · September 26th 2024. "The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of high-risk disease marking key areas of progress," writes Michael S. Cookson, MD, MMHC. September 26th 2024.
All News - Urology Times
PEG hydrogel spacer use shows growth in US men with prostate cancer. Benjamin P. Saylor. October 2nd 2024. Overall, a total of 693 patients received a PEG spacer in 2017 and 2510 received one in 2022, an increase of 262%.
Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC
1 天前 · Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC. The panelist discusses how the ARANOTE trial demonstrated significant benefits of adding darolutamide to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer, showing improvements in radiographic progression-free survival and other key outcomes.
Advancements in Minimally Invasive Surgical Options for the …
2022年3月31日 · Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate affecting more than 40 million men in the United States with an associated prevalence that increases from 40% to 80% among men 50 to 70 years of age, respectively. 1,2 Progression of BPH leads to the subsequent development of lower urinary tract symptoms (LUTS), which most commonly include frequent urination ...
Long-term results of Rezum therapy for patients with large prostates
December 23, 2021. Long-term results of Rezum therapy for patients with large prostates. Author (s): Janelle Hart. Patients with large prostates (LP), defined as greater than 80 grams, are generally limited to certain procedures such as a prostatectomy or transurethral resection of the prostate (TURP) when surgery is required.
Ravi Munver, MD, discusses the versatility of Aquablation …
1 天前 · In this video, Ravi Munver, MD, discusses the versatility of Aquablation with the HYDROS Robotic System for the treatment of benign prostatic hyperplasia. Munver is the vice chair of the department of urology at Hackensack University Medical Center (HUMC), as well as the director of minimally invasive and robotic urologic surgery, …
5-year data sustain long-term effectiveness of Aquablation vs …
2022年2月28日 · Aquablation therapy demonstrated strong efficacy and safety vs transurethral resection of the prostate (TURP) for the treatment of men with lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), according to 5-year results from the pivotal WATER trial published in the Canadian Journal of Urology. 1,2. International Prostate Symptom Score (IPSS) data at 5 years ...
Aquablation demonstrates success in large prostates - Urology …
2021年9月25日 · For patients with large prostate glands who have lower urinary tract symptoms secondary to BPH, surgical treatment options are limited. In a recent study presented at the 2021 American Urological Association Annual Meeting,¹ Naeem Bhojani, MD, FRCSC, David-Dan Nguyen, and co-authors, reported the favorable 3-year results of ongoing Aquablation research specifically involving patients with ...
Optilume drug-coated balloon superior to standard care for …
2021年10月14日 · Interim 1-year results from the pivotal ROBUST III trial showed that the novel Optilume urethral drug-coated balloon improved outcomes versus standard endoscopic management in patients with recurrent anterior urethral strictures. 1. Findings presented during the 2021 International Continence Society Annual Meeting showed the primary end point ...